Balanced Rock Investment Advisors LLC Decreases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Balanced Rock Investment Advisors LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 41.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,460 shares of the company’s stock after selling 1,016 shares during the quarter. Balanced Rock Investment Advisors LLC’s holdings in Johnson & Johnson were worth $231,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. BKM Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at about $1,951,000. Sunflower Bank N.A. raised its position in Johnson & Johnson by 3.3% during the 4th quarter. Sunflower Bank N.A. now owns 10,556 shares of the company’s stock worth $1,655,000 after buying an additional 341 shares during the last quarter. Consilio Wealth Advisors LLC raised its position in Johnson & Johnson by 25.0% during the 4th quarter. Consilio Wealth Advisors LLC now owns 1,785 shares of the company’s stock worth $280,000 after buying an additional 357 shares during the last quarter. RDA Financial Network raised its position in Johnson & Johnson by 7.0% during the 4th quarter. RDA Financial Network now owns 5,615 shares of the company’s stock worth $880,000 after buying an additional 368 shares during the last quarter. Finally, Fortress Wealth Group LLC raised its position in Johnson & Johnson by 7.7% during the 4th quarter. Fortress Wealth Group LLC now owns 6,635 shares of the company’s stock worth $1,072,000 after buying an additional 476 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded down $1.91 during trading on Tuesday, reaching $152.33. The company had a trading volume of 6,260,286 shares, compared to its average volume of 7,324,389. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The firm’s 50-day simple moving average is $148.42 and its 200 day simple moving average is $153.24. The firm has a market capitalization of $366.61 billion, a PE ratio of 9.47, a price-to-earnings-growth ratio of 2.85 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.79%. The company had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter in the previous year, the company posted $2.80 EPS. The firm’s quarterly revenue was up 4.3% on a year-over-year basis. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.26%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on JNJ shares. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, July 1st. The Goldman Sachs Group reduced their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday. TD Cowen cut their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. TD Securities cut their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Sunday, June 30th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.